MedTrace Logo

Artificial Intelligence Combined With 3D-Preformed Chest Wall Defection Reconstruction System in Chest Wall Tumor Surgery

NCT06978075 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-18

No results posted yet for this study

Summary

Chest wall tumors should be completely resection as much as possible while malignant chest wall tumors should be extensively resection. If not completely resection, it will recur in the short time and affect the patient's survival. At present, the surgical resection range mainly relies on preoperative imaging examination and the experience of the surgeon. It lacks precise guidance. This can easily lead to incomplete resection. In addition, the reconstruction materials required for reconstruct the excised chest wall defection are often generated in a standardized manner, lacking intraoperative adjustability. To address this clinical issue, we plan to carry out the research on the application of artificial Intelligence (AI) assisted chest wall tumor resection combined with personalized 3D preformed chest wall defection reconstruction system in chest wall tumor surgery.

Conditions

  • Chest Wall Tumor
  • Reconstruction Surgery

Interventions

DEVICE

Chest wall tumor resection by the artificial intelgent assistent

we plan to carry out of the research on the application of artificial intelligence (AI) assisted chest wall tumor research combined with a personalized 3D preformed chest wall defect reconstruction system in chest wall tumor surgery. Data will be imported into a computer to draw a 3D model of the tumor and construct an ideal resection range to ensuring sufficient surgical margins while avoiding damage to important nerve and vascular tissues in the chest. Preformed titanium plates will be prepared based on the calculated resection range and the titanium plates will be detachable assembly components through screws, which can be adjusted at any time according to the surgical situation.

Sponsors & Collaborators

  • Wu Weiming

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2028-07-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06978075 on ClinicalTrials.gov